The Role of Laryngopharyngeal Reflux in IPF

Part of paid clinical trials in Denver, Colorado.

Sponsor
National Jewish Health
Study ID
NCT03418350
Status
Recruiting
Apply to this trial

Conditions

Eligibility Criteria

Sex
ALL
Age
40 Years - 95 Years
Healthy Volunteers
Not accepted

Study Details

The primary objective of this study is to show that the Supraglottic Index (SGI) is an easily-collected index that accurately identifies the presence and severity of laryngopharyngeal reflux (LPF) in idiopathic pulmonary fibrosis (IPF).

Key Dates

Start date
Aug 1, 2018
Status verified
Nov 2024
Primary completion
Dec 31, 2025
Completion
Dec 31, 2026

Study Design

Enrollment
60 participants (estimated)

Primary Outcome Measure

The supraglottic index (SGI) quantifies laryngopharyngeal reflux (LPF) and is associated with severity of pulmonary fibrosis. [ Time Frame: 6 months ]

Central Contacts

Locations (1)

FacilityCityStateZIPSite coordinators
National Jewish HealthDenverColorado80206
Tara Churney, MPH
[email protected]
303-398-1996

Find similar trials in Denver, CO

By research site
National Jewish Health· Denver, CO

Related Studies